Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 289

1.

Adjuvant chemoradiation in pancreatic cancer: impact of radiotherapy dose on survival.

Morganti AG, Cellini F, Buwenge M, Arcelli A, Alfieri S, Calvo FA, Casadei R, Cilla S, Deodato F, Di Gioia G, Di Marco M, Fuccio L, Bertini F, Guido A, Herman JM, Macchia G, Maidment BW 3rd, Miller RC, Minni F, Passoni P, Valentini C, Re A, Regine WF, Reni M, Falconi M, Valentini V, Mattiucci GC.

BMC Cancer. 2019 Jun 11;19(1):569. doi: 10.1186/s12885-019-5790-2.

2.

Novel EUS-guided brachytherapy treatment of pancreatic cancer with phosphorus-32 microparticles: first United States experience.

Bhutani MS, Cazacu IM, Luzuriaga Chavez AA, Singh BS, Wong FCL, Erwin WD, Tamm EP, Mathew GG, Le DB, Koay EJ, Taniguchi CM, Minsky BD, Pant S, Tzeng CD, Koong AC, Varadhachary GR, Katz MHG, Wolff RA, Fogelman DR, Herman JM.

VideoGIE. 2019 Apr 29;4(5):223-225. doi: 10.1016/j.vgie.2019.02.009. eCollection 2019 May. No abstract available.

3.

Endoscopic Ultrasound-Guided Fiducial Placement for Gastrointestinal Malignancies.

Bhutani MS, Herman JM.

Gastroenterol Hepatol (N Y). 2019 Mar;15(3):167-170. No abstract available.

4.

Effect of setup and inter-fraction anatomical changes on the accumulated dose in CT-guided breath-hold intensity modulated proton therapy of liver malignancies.

Yang Z, Chang Y, Brock KK, Cazoulat G, Koay EJ, Koong AC, Herman JM, Park PC, Poenisch F, Li Q, Yang K, Wu G, Anderson B, Ohrt AN, Li Y, Zhu XR, Zhang X, Li H.

Radiother Oncol. 2019 May;134:101-109. doi: 10.1016/j.radonc.2019.01.028. Epub 2019 Feb 6.

PMID:
31005203
5.

Enhancing clinical trial enrollment at MD Anderson Cancer Center satellite community campuses.

Ludmir EB, Adlakha EK, Chun SG, Reed VK, Arzu IY, Ahmad N, Bloom E, Chronowski GM, Delclos ME, Mayo LL, Schlembach PJ, Liao Z, Koong AC, Herman JM, Shah SJ.

Acta Oncol. 2019 Apr 8:1-3. doi: 10.1080/0284186X.2019.1600019. [Epub ahead of print] No abstract available.

PMID:
30958082
6.

Proton beam therapy outcomes for localized unresectable hepatocellular carcinoma.

Chadha AS, Gunther JR, Hsieh CE, Aliru M, Mahadevan LS, Venkatesulu BP, Crane CH, Das P, Herman JM, Koay EJ, Taniguchi C, Holliday EB, Minsky BD, Suh Y, Park P, Sawakuchi G, Beddar S, Odisio BC, Gupta S, Loyer E, Kaur H, Raghav K, Javle MM, Kaseb AO, Krishnan S.

Radiother Oncol. 2019 Apr;133:54-61. doi: 10.1016/j.radonc.2018.10.041. Epub 2019 Jan 16.

PMID:
30935582
7.

EUS-guided fiducial placement for GI malignancies: a systematic review and meta-analysis.

Coronel E, Cazacu IM, Sakuraba A, Luzuriaga Chavez AA, Uberoi A, Geng Y, Tomizawa Y, Saftoiu A, Shin EJ, Taniguchi CM, Koong AC, Herman JM, Bhutani MS.

Gastrointest Endosc. 2019 Apr;89(4):659-670.e18. doi: 10.1016/j.gie.2018.10.047. Epub 2018 Nov 13. Review.

PMID:
30445001
8.

Dose escalation for locally advanced pancreatic cancer: How high can we go?

Colbert LE, Rebueno N, Moningi S, Beddar S, Sawakuchi GO, Herman JM, Koong AC, Das P, Holliday EB, Koay EJ, Taniguchi CM.

Adv Radiat Oncol. 2018 Oct 23;3(4):693-700. doi: 10.1016/j.adro.2018.07.008. eCollection 2018 Oct-Dec.

9.

Improving prediction of surgical resectability over current staging guidelines in patients with pancreatic cancer who receive stereotactic body radiation therapy.

Cheng Z, Rosati LM, Chen L, Mian OY, Cao Y, Villafania M, Nakatsugawa M, Moore JA, Robertson SP, Jackson J, Hacker-Prietz A, He J, Wolfgang CL, Weiss MJ, Herman JM, Narang AK, McNutt TR.

Adv Radiat Oncol. 2018 Jul 19;3(4):601-610. doi: 10.1016/j.adro.2018.07.002. eCollection 2018 Oct-Dec.

10.

Circulating Nucleic Acids Are Associated With Outcomes of Patients With Pancreatic Cancer.

Bernard V, Kim DU, San Lucas FA, Castillo J, Allenson K, Mulu FC, Stephens BM, Huang J, Semaan A, Guerrero PA, Kamyabi N, Zhao J, Hurd MW, Koay EJ, Taniguchi CM, Herman JM, Javle M, Wolff R, Katz M, Varadhachary G, Maitra A, Alvarez HA.

Gastroenterology. 2019 Jan;156(1):108-118.e4. doi: 10.1053/j.gastro.2018.09.022. Epub 2018 Sep 19.

11.

Prognostic Impact of Presurgical CA19-9 Level in Pancreatic Adenocarcinoma: A Pooled Analysis.

Mattiucci GC, Morganti AG, Cellini F, Buwenge M, Casadei R, Farioli A, Alfieri S, Arcelli A, Bertini F, Calvo FA, Cammelli S, Fuccio L, Giaccherini L, Guido A, Herman JM, Macchia G, Maidment BW 3rd, Miller RC, Minni F, Regine WF, Reni M, Partelli S, Falconi M, Valentini V.

Transl Oncol. 2019 Jan;12(1):1-7. doi: 10.1016/j.tranon.2018.08.017. Epub 2018 Sep 17.

12.

Update on Requirements for Medical Dosimetry Certification in the United States.

Soisson E, Lembesis F, Baacke D, DeMarco ML, Herman JM.

Int J Radiat Oncol Biol Phys. 2018 Oct 1;102(2):251-253. doi: 10.1016/j.ijrobp.2018.05.065. No abstract available.

PMID:
30191857
13.

Dose escalation of radiotherapy in unresectable extrahepatic cholangiocarcinoma.

Elganainy D, Holliday EB, Taniguchi CM, Smith GL, Shroff R, Javle M, Raghav K, Kaseb A, Aloia TA, Vauthey JN, Tzeng CD, Herman JM, Koong AC, Krishnan SX, Minsky BD, Crane CH, Das P, Koay EJ.

Cancer Med. 2018 Oct;7(10):4880-4892. doi: 10.1002/cam4.1734. Epub 2018 Aug 27.

14.

Neoadjuvant PET and MRI-based intensity modulated radiotherapy leads to less toxicity and improved pathologic response rates in locally advanced rectal cancer.

David JM, Gresham G, Jabbour SK, Deek M, Thomassian S, Robertson JM, Newman NB, Herman JM, Osipov A, Kabolizadeh P, Tuli R.

J Gastrointest Oncol. 2018 Aug;9(4):641-649. doi: 10.21037/jgo.2018.03.10.

15.

Hyperfractionated abdominal reirradiation for gastrointestinal malignancies.

Hunt A, Das P, Minsky BD, Koay EJ, Krishnan S, Herman JM, Taniguchi C, Koong A, Smith GL, Holliday EB.

Radiat Oncol. 2018 Aug 7;13(1):143. doi: 10.1186/s13014-018-1084-0.

16.

Dose Prediction Model for Duodenum Sparing With a Biodegradable Hydrogel Spacer for Pancreatic Cancer Radiation Therapy.

Feng Z, Rao AD, Cheng Z, Shin EJ, Moore J, Su L, Kim SH, Wong J, Narang A, Herman JM, McNutt T, Li D, Ding K.

Int J Radiat Oncol Biol Phys. 2018 Nov 1;102(3):651-659. doi: 10.1016/j.ijrobp.2018.07.184. Epub 2018 Jul 19.

17.

Comparing Ablative Modalities for Hepatocellular Carcinoma: Cautions in Interpreting Big Data.

Smith GL, Das P, Herman JM, Koay EJ, Koong AC, Grossberg A, Ludmir E.

J Clin Oncol. 2018 Aug 20;36(24):2565-2566. doi: 10.1200/JCO.2018.78.5428. Epub 2018 Jun 26. No abstract available.

PMID:
29945520
18.

Stereotactic body radiation therapy for palliative management of pancreatic adenocarcinoma in elderly and medically inoperable patients.

Ryan JF, Rosati LM, Groot VP, Le DT, Zheng L, Laheru DA, Shin EJ, Jackson J, Moore J, Narang AK, Herman JM.

Oncotarget. 2018 Mar 27;9(23):16427-16436. doi: 10.18632/oncotarget.24713. eCollection 2018 Mar 27.

19.

Definitive radiation therapy for hepatocellular carcinoma with portal vein tumor thrombus.

Holliday EB, Tao R, Brownlee Z, Das P, Krishnan S, Taniguchi C, Minsky BD, Herman JM, Kaseb A, Raghav K, Conrad C, Vauthey JN, Aloia TA, Chun YS, Crane CH, Koay EJ.

Clin Transl Radiat Oncol. 2017 Jun 7;4:39-45. doi: 10.1016/j.ctro.2017.04.003. eCollection 2017 Jun.

20.

Long-term analysis of 2 prospective studies that incorporate mitomycin C into an adjuvant chemoradiation regimen for pancreatic and periampullary cancers.

Schunke KJ, Rosati LM, Zahurak M, Herman JM, Narang AK, Usach I, Klein AP, Yeo CJ, Korman LT, Hruban RH, Cameron JL, Laheru DA, Abrams RA.

Adv Radiat Oncol. 2017 Aug 3;3(1):42-51. doi: 10.1016/j.adro.2017.07.008. eCollection 2018 Jan-Mar.

21.

Stereotactic Radiotherapy and Particle Therapy for Pancreatic Cancer.

Ng SP, Herman JM.

Cancers (Basel). 2018 Mar 16;10(3). pii: E75. doi: 10.3390/cancers10030075. Review.

22.

Postoperative complications after resection of borderline resectable and locally advanced pancreatic cancer: The impact of neoadjuvant chemotherapy with conventional radiation or stereotactic body radiation therapy.

Blair AB, Rosati LM, Rezaee N, Gemenetzis G, Zheng L, Hruban RH, Cameron JL, Weiss MJ, Wolfgang CL, Herman JM, He J.

Surgery. 2018 May;163(5):1090-1096. doi: 10.1016/j.surg.2017.11.027. Epub 2018 Mar 12.

23.

Imaging-based biomarkers: Changes in the tumor interface of pancreatic ductal adenocarcinoma on computed tomography scans indicate response to cytotoxic therapy.

Amer AM, Zaid M, Chaudhury B, Elganainy D, Lee Y, Wilke CT, Cloyd J, Wang H, Maitra A, Wolff RA, Varadhachary G, Overman MJ, Lee JE, Fleming JB, Tzeng CW, Katz MH, Holliday EB, Krishnan S, Minsky BD, Herman JM, Taniguchi CM, Das P, Crane CH, Le O, Bhosale P, Tamm EP, Koay EJ.

Cancer. 2018 Apr 15;124(8):1701-1709. doi: 10.1002/cncr.31251. Epub 2018 Jan 25.

24.

Is a Pathological Complete Response Following Neoadjuvant Chemoradiation Associated With Prolonged Survival in Patients With Pancreatic Cancer?

He J, Blair AB, Groot VP, Javed AA, Burkhart RA, Gemenetzis G, Hruban RH, Waters KM, Poling J, Zheng L, Laheru D, Herman JM, Makary MA, Weiss MJ, Cameron JL, Wolfgang CL.

Ann Surg. 2018 Jul;268(1):1-8. doi: 10.1097/SLA.0000000000002672.

25.

Smad4 Loss Correlates With Higher Rates of Local and Distant Failure in Pancreatic Adenocarcinoma Patients Receiving Adjuvant Chemoradiation.

Herman JM, Jabbour SK, Lin SH, Deek MP, Hsu CC, Fishman EK, Kim S, Cameron JL, Chekmareva M, Laheru DA, Narang AK, Pawlik TM, Hruban RH, Wolfgang CL, Iacobuzio-Donahue CA.

Pancreas. 2018 Feb;47(2):208-212. doi: 10.1097/MPA.0000000000000985.

26.

Short course radiation as a component of definitive multidisciplinary treatment for select patients with metastatic rectal adenocarcinoma.

Holliday EB, Hunt A, You YN, Chang GJ, Skibber JM, Rodriguez-Bigas MA, Bednarski BK, Eng C, Koay EJ, Minsky BD, Taniguchi C, Krishnan S, Herman JM, Das P.

J Gastrointest Oncol. 2017 Dec;8(6):990-997. doi: 10.21037/jgo.2017.09.02.

27.

A rare case of esophageal metastasis from pancreatic ductal adenocarcinoma: a case report and literature review.

Rosati LM, Kummerlowe MN, Poling J, Hacker-Prietz A, Narang AK, Shin EJ, Le DT, Fishman EK, Hruban RH, Yang SC, Weiss MJ, Herman JM.

Oncotarget. 2017 Jun 12;8(59):100942-100950. doi: 10.18632/oncotarget.18458. eCollection 2017 Nov 21.

28.

Multiplex Proximity Ligation Assay to Identify Potential Prognostic Biomarkers for Improved Survival in Locally Advanced Pancreatic Cancer Patients Treated With Stereotactic Body Radiation Therapy.

Rao AD, Liu Y, von Eyben R, Hsu CC, Hu C, Rosati LM, Parekh A, Ng K, Hacker-Prietz A, Zheng L, Pawlik TM, Laheru DA, Jaffee EM, Weiss MJ, Le DT, Hruban RH, De Jesus-Acosta A, Wolfgang CL, Narang AK, Chang DT, Koong AC, Herman JM.

Int J Radiat Oncol Biol Phys. 2018 Feb 1;100(2):486-489. doi: 10.1016/j.ijrobp.2017.10.001. Epub 2017 Oct 12.

PMID:
29157747
29.

The role of imaging in the clinical practice of radiation oncology for pancreatic cancer.

Koay EJ, Hall W, Park PC, Erickson B, Herman JM.

Abdom Radiol (NY). 2018 Feb;43(2):393-403. doi: 10.1007/s00261-017-1373-3. Review.

30.

Adjuvant Chemoradiotherapy is Associated with Improved Survival for Patients with Resected Gallbladder Carcinoma: A Systematic Review and Meta-analysis.

Kim BH, Kwon J, Chie EK, Kim K, Kim YH, Seo DW, Narang AK, Herman JM.

Ann Surg Oncol. 2018 Jan;25(1):255-264. doi: 10.1245/s10434-017-6139-1. Epub 2017 Oct 27.

PMID:
29079926
31.

Stereotactic Body Radiation Therapy for Isolated Local Recurrence After Surgical Resection of Pancreatic Ductal Adenocarcinoma Appears to be Safe and Effective.

Ryan JF, Groot VP, Rosati LM, Hacker-Prietz A, Narang AK, McNutt TR, Jackson JF, Le DT, Jaffee EM, Zheng L, Laheru DA, He J, Pawlik TM, Weiss MJ, Wolfgang CL, Herman JM.

Ann Surg Oncol. 2018 Jan;25(1):280-289. doi: 10.1245/s10434-017-6134-6. Epub 2017 Oct 23.

PMID:
29063299
32.

Prognostic and Predictive Clinicopathologic Factors of Squamous Anal Canal Cancer in HIV-Positive and HIV-Negative Patients: Does HAART Influence Outcomes?

Pappou EP, Magruder JT, Fu T, Hicks CW, Herman JM, Fang S, Wick EC, Safar B, Gearhart SL, Efron JE.

World J Surg. 2018 Mar;42(3):876-883. doi: 10.1007/s00268-017-4201-6.

33.

A Novel Absorbable Radiopaque Hydrogel Spacer to Separate the Head of the Pancreas and Duodenum in Radiation Therapy for Pancreatic Cancer.

Rao AD, Feng Z, Shin EJ, He J, Waters KM, Coquia S, DeJong R, Rosati LM, Su L, Li D, Jackson J, Clark S, Schultz J, Hutchings D, Kim SH, Hruban RH, DeWeese TL, Wong J, Narang A, Herman JM, Ding K.

Int J Radiat Oncol Biol Phys. 2017 Dec 1;99(5):1111-1120. doi: 10.1016/j.ijrobp.2017.08.006. Epub 2017 Aug 14.

34.

The Potential of Heavy-Ion Therapy to Improve Outcomes for Locally Advanced Non-Small Cell Lung Cancer.

Chun SG, Solberg TD, Grosshans DR, Nguyen QN, Simone CB 2nd, Mohan R, Liao Z, Hahn SM, Herman JM, Frank SJ.

Front Oncol. 2017 Sep 5;7:201. doi: 10.3389/fonc.2017.00201. eCollection 2017. No abstract available.

35.

SBRT for Unresectable Pancreatic Cancer Can Improve Local Control With Minimal Toxicity.

Ng SP, Herman JM.

Int J Radiat Oncol Biol Phys. 2017 Oct 1;99(2):298-299. doi: 10.1016/j.ijrobp.2017.05.034. No abstract available.

PMID:
28871974
36.

High dose-rate Intra-Operative Radiation Therapy During High Risk Genitourinary Surgery: Initial Observations and a Proposal for its Study in Bladder Cancer.

Kates M, Chappidi MR, Brant A, Milbar N, Sopko NA, Meyer C, Terezakis SA, Herman JM, Efron JE, Safar B, Tran PT, Ahuja N, Pierorazio PM, Bivalacqua TJ.

Bladder Cancer. 2017 Jul 27;3(3):191-199. doi: 10.3233/BLC-170104.

37.

Alliance for clinical trials in oncology (ALLIANCE) trial A021501: preoperative extended chemotherapy vs. chemotherapy plus hypofractionated radiation therapy for borderline resectable adenocarcinoma of the head of the pancreas.

Katz MHG, Ou FS, Herman JM, Ahmad SA, Wolpin B, Marsh R, Behr S, Shi Q, Chuong M, Schwartz LH, Frankel W, Collisson E, Koay EJ, Hubbard JM, Leenstra JL, Meyerhardt J, O'Reilly E; Alliance for Clinical Trials on Oncology.

BMC Cancer. 2017 Jul 27;17(1):505. doi: 10.1186/s12885-017-3441-z.

38.

Association of Clinical Factors With a Major Pathologic Response Following Preoperative Therapy for Pancreatic Ductal Adenocarcinoma.

Cloyd JM, Wang H, Egger ME, Tzeng CD, Prakash LR, Maitra A, Varadhachary GR, Shroff R, Javle M, Fogelman D, Wolff RA, Overman MJ, Koay EJ, Das P, Herman JM, Kim MP, Vauthey JN, Aloia TA, Fleming JB, Lee JE, Katz MHG.

JAMA Surg. 2017 Nov 1;152(11):1048-1056. doi: 10.1001/jamasurg.2017.2227.

39.

An unusual genomic variant of pancreatic ductal adenocarcinoma with an indolent clinical course.

Kohutek ZA, Rosati LM, Hong J, Poling J, Attiyeh MA, Makohon-Moore A, Herman JM, Iacobuzio-Donahue CA.

Cold Spring Harb Mol Case Stud. 2017 Jul 5;3(4). pii: a001701. doi: 10.1101/mcs.a001701. Print 2017 Jul.

40.

Long-term survival benefit of upfront chemotherapy in patients with newly diagnosed borderline resectable pancreatic cancer.

Shrestha B, Sun Y, Faisal F, Kim V, Soares K, Blair A, Herman JM, Narang A, Dholakia AS, Rosati L, Hacker-Prietz A, Chen L, Laheru DA, De Jesus-Acosta A, Le DT, Donehower R, Azad N, Diaz LA, Murphy A, Lee V, Fishman EK, Hruban RH, Liang T, Cameron JL, Makary M, Weiss MJ, Ahuja N, He J, Wolfgang CL, Huang CY, Zheng L.

Cancer Med. 2017 Jul;6(7):1552-1562. doi: 10.1002/cam4.1104. Epub 2017 Jun 21.

41.

Strategies to tackle the challenges of external beam radiotherapy for liver tumors.

Lock MI, Klein J, Chung HT, Herman JM, Kim EY, Small W, Mayr NA, Lo SS.

World J Hepatol. 2017 May 18;9(14):645-656. doi: 10.4254/wjh.v9.i14.645. Review.

42.

Integration of Stereotactic Body Radiation Therapy into the Multidisciplinary Management of Pancreatic Cancer.

Rosati LM, Kumar R, Herman JM.

Semin Radiat Oncol. 2017 Jul;27(3):256-267. doi: 10.1016/j.semradonc.2017.02.005. Epub 2017 Feb 20. Review.

PMID:
28577833
43.

Feasibility study of ultrasound imaging for stereotactic body radiation therapy with active breathing coordinator in pancreatic cancer.

Su L, Iordachita I, Zhang Y, Lee J, Ng SK, Jackson J, Hooker T, Wong J, Herman JM, Sen HT, Kazanzides P, Lediju Bell MA, Yang C, Ding K.

J Appl Clin Med Phys. 2017 Jul;18(4):84-96. doi: 10.1002/acm2.12100. Epub 2017 Jun 2.

44.

ACR Appropriateness Criteria® Pretreatment Staging of Colorectal Cancer.

Expert Panel on Gastrointestinal Imaging:, Fowler KJ, Kaur H, Cash BD, Feig BW, Gage KL, Garcia EM, Hara AK, Herman JM, Kim DH, Lambert DL, Levy AD, Peterson CM, Scheirey CD, Small W Jr, Smith MP, Lalani T, Carucci LR.

J Am Coll Radiol. 2017 May;14(5S):S234-S244. doi: 10.1016/j.jacr.2017.02.012. Review.

PMID:
28473079
45.

Personalized Management of Pancreatic Ductal Adenocarcinoma Patients through Computational Modeling.

Yamamoto KN, Yachida S, Nakamura A, Niida A, Oshima M, De S, Rosati LM, Herman JM, Iacobuzio-Donahue CA, Haeno H.

Cancer Res. 2017 Jun 15;77(12):3325-3335. doi: 10.1158/0008-5472.CAN-16-1208. Epub 2017 Apr 5.

46.

What Advanced Practitioners Need to Know About the Diagnosis and Treatment of Patients With Pancreatic Cancer.

Herman JM, Hacker-Prietz A.

J Adv Pract Oncol. 2017 Apr;8(3):255-260. Epub 2017 Apr 1. Review.

47.

Role of Stereotactic Body Radiotherapy in the Treatment of Elderly and Poor Performance Status Patients With Pancreatic Cancer.

Rosati LM, Herman JM.

J Oncol Pract. 2017 Mar;13(3):157-166. doi: 10.1200/JOP.2016.020628. Review.

PMID:
28282277
48.

ACR Appropriateness Criteria® Resectable Pancreatic Cancer.

Jones WE 3rd, Suh WW, Abdel-Wahab M, Abrams RA, Azad N, Das P, Dragovic J, Goodman KA, Jabbour SK, Konski AA, Koong AC, Kumar R, Lee P, Pawlik TM, Small W Jr, Herman JM; Expert Panel on Radiation OncologyGastrointestinal.

Am J Clin Oncol. 2017 Apr;40(2):109-117. doi: 10.1097/COC.0000000000000370. Review.

PMID:
28230650
49.

A final report of a phase I study of veliparib (ABT-888) in combination with low-dose fractionated whole abdominal radiation therapy (LDFWAR) in patients with advanced solid malignancies and peritoneal carcinomatosis with a dose escalation in ovarian and fallopian tube cancers.

Reiss KA, Herman JM, Armstrong D, Zahurak M, Fyles A, Brade A, Milosevic M, Dawson LA, Scardina A, Fischer P, Hacker-Prietz A, Kinders RJ, Wang L, Chen A, Temkin S, Horiba N, Stayner LA, Siu LL, Azad NS.

Gynecol Oncol. 2017 Mar;144(3):486-490. doi: 10.1016/j.ygyno.2017.01.016. Epub 2017 Jan 18.

50.

Systematic review on the treatment of isolated local recurrence of pancreatic cancer after surgery; re-resection, chemoradiotherapy and SBRT.

Groot VP, van Santvoort HC, Rombouts SJ, Hagendoorn J, Borel Rinkes IH, van Vulpen M, Herman JM, Wolfgang CL, Besselink MG, Molenaar IQ.

HPB (Oxford). 2017 Feb;19(2):83-92. doi: 10.1016/j.hpb.2016.11.001. Epub 2017 Jan 3. Review.

Supplemental Content

Loading ...
Support Center